Fusion Antibodies PLC (FAB) — Cash Flow-to-Debt Ratio
Fusion Antibodies PLC (FAB) has a Cash Flow-to-Debt Ratio of -0.53x as of September 2025, meaning its operating cash flow of GBX-575.00K could theoretically repay -1% of its total liabilities (GBX1.09 Million) in one year. See cash generation quality of Fusion Antibodies PLC to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Fusion Antibodies PLC Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Fusion Antibodies PLC across 11 annual periods. Also explore net asset growth rate of Fusion Antibodies PLC to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Fusion Antibodies PLC (2015–2025)
Year-by-year debt coverage analysis for Fusion Antibodies PLC. For market capitalisation and broader financial context, see Fusion Antibodies PLC (FAB) total market value.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.09x | GBX-1.36 Million | GBX654.00K | ▲ +26.1% |
| 2024 | -2.82x | GBX-1.77 Million | GBX627.00K | ▼ -51.0% |
| 2023 | -1.87x | GBX-1.75 Million | GBX939.00K | ▼ -597.2% |
| 2022 | -0.27x | GBX-330.00K | GBX1.23 Million | ▲ +74.8% |
| 2021 | -1.06x | GBX-1.15 Million | GBX1.08 Million | ▼ -686.2% |
| 2020 | -0.14x | GBX-166.00K | GBX1.23 Million | ▲ +89.1% |
| 2019 | -1.24x | GBX-1.10 Million | GBX888.53K | ▼ -1114.6% |
| 2018 | 0.12x | GBX77.19K | GBX633.59K | ▲ +246.8% |
| 2017 | -0.08x | GBX-37.37K | GBX450.22K | ▼ -109.9% |
| 2016 | 0.84x | GBX346.57K | GBX411.43K | ▲ +193.3% |
| 2015 | -0.90x | GBX-182.05K | GBX201.67K | — |